STOCKHOLM, Dec. 15, 2021 /PRNewswire/ — Calliditas Therapeutics AB (Nasdaq: CALT) (Nasdaq Stockholm: CALTX) ("Calliditas") today announced that the US Food and Drug Administration (FDA) has approved Tarpeyo (budesonide) delayed release capsules to…Original Article
FDA Approves Tarpeyo (budesonide) to Reduce Proteinuria in IgA Nephropathy
